Tibet-based drugmaker; main product Xinhuosu, an injected recombinant BNP drug for acute heart failure, plus Tibetan and Chinese medicines.
Tibet-based drugmaker; main product Xinhuosu, an injected recombinant BNP drug for acute heart failure, plus Tibetan and Chinese medicines.
Relies on one drug: Xinhuosu, an injection for acute heart failure that has been the only product of its type made in China, so most sales come from a single product under hospital purchasing rules. Its older Tibetan-herb lines, such as the rhodiola capsules, are far smaller. Capacity is being expanded to meet demand.
Moat: narrow (IP / patents, regulatory licence). Xinhuosu has long been the only domestic product of its kind, a national class-1 biologic.
Founded: 1999 · Employees: 671
Size Tibet Rhodiola Pharmaceutical (600211.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.87B, the 1233rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥38.70 on 18 Nov 2026.
Performance Over six months the shares fell 8.4%, against -9.3% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 12.8% over the last twelve months (peer median +10.7%); the operating margin is 27.5% (peer median 13.3%).
Valuation It trades at 12.5× forward earnings against a peer median of 19.6× (6th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -18 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 31.2 points above its cost of capital (7.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.07B | CN¥2.95B | CN¥2.78B | CN¥3.10B | CN¥2.53B |
| Revenue growth | — | +6% | -11% | +23% | — |
| Gross profit | CN¥2.89B | CN¥2.74B | CN¥2.58B | CN¥2.92B | CN¥2.35B |
| EBITDA | n/a | CN¥1.00B | CN¥968M | CN¥1.10B | CN¥759M |
| Net income | CN¥992M | CN¥938M | CN¥1.05B | CN¥801M | CN¥370M |
| Free cash flow | CN¥1.10B | CN¥1.01B | CN¥979M | CN¥1.06B | CN¥748M |
| Capital expenditure | CN¥22.1M | CN¥16.0M | CN¥37.6M | CN¥21.7M | CN¥102M |
| Total debt | CN¥1.25B | CN¥841M | CN¥273M | CN¥502M | CN¥488M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600211.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.3% | +0.7% | 5th highest of 21 |
| 6-month return | -8.4% | -9.3% | 11th highest of 21 |
| Distance from 52-week high | -21.0% | -28.3% | 8th highest of 21 |
| Revenue growth (TTM) | +12.8% | +10.7% | 9th highest of 20 |
| Operating margin | 27.5% | 13.3% | 5th highest of 20 |
| Forward P/E | 12.5× | 19.6× | 6th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -1.2% | 3.3% | 5th least demanding of 13 |
| Growth delivered (Del g) | +16.7% | +6.8% | 3rd highest of 13 |
| Hurdle (Req g minus delivered) | -18.0 pp | -6.3 pp | 3rd least demanding of 13 |
| ROIC minus cost of capital | +31.2 pp | +0.1 pp | 3rd highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 12.5× | -1.2% | +16.7% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% | +9.3% |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 96.3× | n/a | n/a |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $1.85B | -38% | +5% | -18% | n/a | n/a | n/a |
| Dermapharm DMP.DE | Germany | $1.85B | -29% | +2% | 21% | 13.2× | -3.4% | +8.0% |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.83B | -25% | +17% | 33% | 13.0× | 5.4% | +29.1% |
| Guobang Pharma 605507.SS | China | $1.82B | -6% | +3% | 12% | 15.7× | -6.0% | +7.4% |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 9.4× | 1.2% | +14.1% |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 10.4× | n/a | n/a |
| Jinyu Bio-Technology 600201.SS | China | $1.93B | -21% | +22% | 10% | 59.0× | 23.4% | -2.5% |
| China National Accord Medicines 000028.SZ | China | $1.81B | -3% | 0% | 2% | 10.8× | -9.5% | +4.2% |
| Zymeworks ZYME | United States | $1.81B | +5% | +98% | 17% | 160.4× | n/a | n/a |
| Harmony Biosciences HRMY | United States | $1.94B | +6% | +20% | 22% | 8.6× | -10.5% | +40.3% |
| Ultragenyx Pharmaceutical RARE | United States | $1.81B | -24% | +16% | -64% | 9.6× | n/a | n/a |
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 21.0× | 10.1% | +5.0% |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.95B | -14% | +11% | 6% | 44.6× | n/a | n/a |
| Shenzhen Hepalink Pharmaceutical 002399.SZ | China | $1.80B | -12% | -6% | 8% | 25.8× | -0.7% | +0.5% |
| Biohaven BHVN | United States | $1.95B | +46% | n/a | n/a | n/a | n/a | n/a |